Discounting role in cost-effectiveness of HPV vaccination by Starkie Camejo et al. (Public Health Vol 129(7):989–92)

Public Health

Volume 132, March 2016, Pages 108-109

None sought.

None declared.

TB; RD and NL are employees of Sanofi Pasteur MSD.

H. Starkie Camejo et al.
Does it matter? Discounting and its role in the cost-effectiveness of preventative interventions. The case of HPV vaccination
Public Health
(2015 Jul)
M. Brisson et al.
Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modelling study
Vaccine
(2013)
S.N. Tabrizi et al.
Assessment of herd immunity and cross protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
Lancet Infect Dis
(2014)
T. Malagón et al.
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review meta-analysis
Lancet Infect Dis
(2012)
P.L. McCormack
Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil^®): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts
Drugs
(2014)
M. Jit et al.
Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model
BMJ
(2011)
World Health Organization
Comprehensive cervical cancer control: a guide to essential practice
(2014)

There are more references available in the full text version of this article.